Publication | Closed Access

Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage III Epithelial Ovarian Cancer: A Southwest Oncology Group Trial (SWOG-9326)

Oral AltretamineOncologyPhase Ii TrialMedicineGynecologyPharmacotherapyCancer TreatmentPharmacologyGynecology OncologyClinical Complete RemissionEndocrine-related CancerOvarian Cancer